Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.50 |
| ▸ | AXL | P30530 | 3/20 | 0.50 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 4/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892846 | 0.95 | AXL (0.51) | KDRAXLMETAURKALCK | |
| SCHEMBL29558086 | 0.95 | AXL (0.51) | KDRAXLMETAURKALCK | |
| SCHEMBL6004313 | 0.86 | GAA (0.51) | KDRAXLSRCPDGFRATGFBR1 | |
| SCHEMBL6004853 | 0.84 | IRAK4 (0.53) | KDRMETAURKALCKTEK | |
| SCHEMBL22505727 | 0.83 | FLT1 (0.45) | KDRAXLMETAURKALCK | |
| SCHEMBL22959958 | 0.82 | CYP1A2 (0.40) | KDRAXLMETAURKALCK | |
| SCHEMBL1132184 | 0.81 | GAA (0.51) | KDRAXLMETAURKBSRC | |
| SCHEMBL22959957 | 0.81 | LMNA (0.55) | KDRAXLMETAURKALCK | |
| SCHEMBL21198921 | 0.80 | KDR (0.42) | KDRAXLMETAURKALCK | |
| SCHEMBL23753739 | 0.80 | AXL (0.52) | KDRAXLMETAURKALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2022-07-28 | — | — | US | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| CN-114206883-A | Oxopyridine fused ring derivative and pharmaceutical composition comprising the same | 伟迈可生物有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-1994024-A2 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | KDR 2118/4885AXL 3328/4885MET 3523/4885 |
| US-20220235064-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ROS1, ROR1, RET | KDR 603/4885AXL 377/4885MET 63/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | KDR 2277/4885AXL 3664/4885MET 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.